|
Management
Dr. Mahendra N. Deshpande is a President and Chief Executive Officer. His forte is creativity in problem solving, development of novel synthetic routes / processes for bulk drug synthesis, successful implementation of technology in kilo-labs and manufacturing plants. He has managed multiple projects and led a team of scientists (Ph.Ds. and Chem. Engineers). In his 12 years of tenure at Abbott Labs, he developed a number of processes for bulk drug manufacturing from bench to plant. He has published extensively in peer-reviewed journal and made number of scientific presentation worldwide. Dr. Deshpande earned his B.Sc. (Hons.) and M.Sc. degrees from India. He earned another MS degree (Organic Chemistry) at Wichita State University, and a Ph.D. degree in Organic Chemistry at University of Wisconsin, Milwaukee. He completed postdoctoral assignments at Research Triangle Institute in Research Triangle Park, NC and University of North Texas. He was a group leader / Sr. Research Investigator in Process R & D at Abbott Laboratories, N. Chicago, IL, where he oversaw projects in chemical route selection, process development and scaleup in kilolab and pilot plants in USA and Europe. He was the recipient of the Bob Stein award and Chairman's awards for outstanding scientific contributions to several neuroscience projects.
Dr. Rajendra C. Shah is a President and Chief Operating Officer. He received his Ph. D. from Sardar Patel University, India. He has over 20 years of research and development experience in different areas of pharmaceutical research, such as Process R & D, analytical and formulation. During his 10 years of service at Abbott Laboratory, IL, he developed chemical processes in the lab and transferred the technolologies to pilot plant and manufacturing in USA and Europe. He demonstrated creativity and leadership in problem solving in process development, polymorphism, crystallization, purification and isolation. Furthermore. he successfully completed process justification for a bulk pharmaceuticals' manufacturing process in order to bring them into compliance with the latest FDA/EPA guide lines. He has handled controlled drug projects and made cGMP deliveries in USA and Europe. Prior to his tenure in Abbott Labs, Dr.Shah was Sr. Scientist at Lyphomed, IL, where he was responsible for cGMP formulation and Quality Control in a GLP Laboratory (regulated by FDA/EPA and OSHA regulations and guidelines). He managed over 100 formulation products and their analysis. Dr.Shah held a position of Process R &D Manager at Themis Pharmaceutical Ltd., India, where he led a team of chemists and engineers. He developed a highly cost efficient process for resolution of D2-aminobutanol.
Dr. Robert M. Moriarty is a Chief Scientific Officer. Dr. Moriarty received his Ph.D. degree from Princeton University. After completing his postdoctoral assignment at University of Munich and Harvard University, he worked as research chemist at Merck from 1955-57. He founded Steroids Limited in 1981 which became SynQuest Limited and later acquired by United Therapeutics in year 2000 . Dr. Moriarty has authored over 200 articles on various topics in synthetic and mechanistic organic synthesis. He is a recipient of several prestigious awards and grants, ACS award for Creative Research & Applications of Iodine Chemistry for 2005 being the most recent one.
Dr. Moriarty has also held appointments at University of Strasbourg (1967), Karolinska Institute (1968), University of Geneva (1974), National Institute of Health (1975), University of Marseille(1976), and University of Erlangen(1976).
Prof. Philip Eugene Eaton is a member of the Scientific Advisory board of OrgSyn Laboratory, Inc.. Prof. Eaton is also a Professor Emeritus at the Department of Chemistry in University of Chicago. He received his B.A. degree in 1957 from Princeton University and his Ph.D. degree in 1961 from Harvard University. He is best known for the synthesis of new organic compounds, including Cubane, Octanitrocubane, [n.2.2.2]Paddalanes, Peristylanes, [2.2.2]Propellanes etc. He has authored over 200 articles on various topics in synthetic and physical organic chemistry. He received the Alexander von Humboldt Prize (Germany) in 1985 and Arthur C. Cope Award in 1997, Yamada Foundation Award in 1999, among many other distinction.
Prof. Eaton has also held visiting professorships at University of Colorado (1971), Stanford University (1974), Universität Freiburg (1986), Universität Köln (1988), Universität Würzburg (1989) and Max Planck Institute fur Polymerforchung, Mainz (1996).
Dr. Richard J. Pariza is a member of the Scientific Advisory board of OrgSyn Laboratory, Inc. He is also Vice President, Science and Technology, for Cedarburg Pharmaceuticals, Inc., in Grafton, WI, and an officer and Board Member for OncQuest, Inc. He has had over 20 years of leadership on major projects in the pharmaceutical industry, as Department Manager of Process Research at Abbott Laboratories, Vice President of Chemistry for Protarga, Inc., and a consultant to several major pharmaceutical companies. He was the chairman of a prestigious IUPAC Symposium and has served on/chaired national ACS committees. He was frequently invited to chair sessions and lead discussions at international scientific conferences. He was a founding Associate Editor for Organic Process Research & Development , the research publication of the American Chemical Society for process research, and now serves on the Editorial Board. He has more than 20 peer-reviewed publications and 10 patents, and continues to be active in chemical research.
|
